×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Videos
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Street likes Luna wet AMD phase II but Adverum wanes
BioWorld MedTech
With Adverum Biotechnologies Inc.'s preliminary safety and efficacy data made public from the ongoing Luna phase II trial testing gene...
2 months ago
Adverum Biotechnologies Announces $127.5 Million Private Placement Financing
GlobeNewswire
Financing led by TCGX with participation from new and existing investors including 5AM Ventures, Commodore Capital, Frazier Life Sciences,...
2 months ago
10 gene therapy companies you should know about
Labiotech.eu
Explore 10 gene therapy companies operating within the biotech industry, as each one hopes to develop their own novel candidates.
2 months ago
Gene Therapies for Cardiomyopathies Market to Witness Growth by 2032
openPR.com
Press release - DelveInsight Business Research LLP - Gene Therapies for Cardiomyopathies Market to Witness Growth by 2032 | Adverum...
2 days ago
Healthcare Stocks on the Move Friday: INBS, ATRA, TYRA, ADVM, CING, GNPX, WXXWY, FGEN
InvestorsObserver
These Healthcare stocks are trading higher: -Intelligent Bio Solutions Inc (INBS) stock is trading at $5.00, a gain of $2.59, or 112.03%,...
3 months ago
Adverum Biotechnologies Presents Nonclinical Data in Support of Ixo-vec's Phase 2 Clinical Development at ASGCT ...
Yahoo Finance
REDWOOD CITY, Calif., May 18, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to...
11 months ago
Adverum lays off staff, funnels cash to single eye candidate
Fierce Biotech
Adverum Biotechnologies is slashing its workforce by nearly 40%, cutting 78 employees under a new restructuring plan.
21 months ago
Adverum Slashes Workforce By 38%, Hones In On Eye Disease Candidate
BioSpace
Adverum Biotechnologies is cutting 78 jobs after announcing it had successfully amended its Investigational New Drug application for...
21 months ago
Foley Represents TCGX as Lead Investor in $127.5M Private Placement for Adverum Biotechnologies
Foley & Lardner LLP
Foley & Larder LLP represented TCG Crossover as the lead investor in the $127.5 million private placement for Adverum Biotechnologies.
2 months ago
Is Adverum Biotechnologies Inc (ADVM) a Smart Choice in Biotechnology Friday?
InvestorsObserver
Adverum Biotechnologies Inc (ADVM) is near the top in its industry group according to InvestorsObserver. ADVM gets an overall rating of 57.
3 months ago